Reporter brief
Comparative Study of Tirzepatide vs Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
What happened
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Observational design with insurance claims data cannot establish causal effects or rule out unmeasured confounding; differences between drug groups may reflect treatment selection patterns rather than drug effects
- Emulating trial design in observational data does not overcome the fundamental limitations of non-randomised comparisons or ensure comparable baseline characteristics across groups
- The abstract does not report outcomes, effect sizes, or sample characteristics, preventing verification of findings or assessment of generalisability
Study design and sample
Observational; Human.
Participants with Type 2 Diabetes
- Design
- Observational
- Sample
- —
- Journal
- Brigham and Women's Hospital
- Published
- Sep 18, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.